Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him

Private label OTC business is likely to be strengthened as Perrigo’s core, as CEO Hendrickson announces retirement shortly after hedge fund investor Starboard Value, pushing to divest the Rx business, built a five-seat block on Perrigo's board.

More from Generics

More from Biosimilars & Generics